Australia markets open in 2 hours 38 minutes
  • ALL ORDS

    7,536.10
    -21.70 (-0.29%)
     
  • AUD/USD

    0.7090
    -0.0019 (-0.26%)
     
  • ASX 200

    7,225.20
    -10.70 (-0.15%)
     
  • OIL

    67.00
    +1.43 (+2.18%)
     
  • GOLD

    1,768.40
    -15.90 (-0.89%)
     
  • BTC-AUD

    80,204.98
    -1,037.80 (-1.28%)
     
  • CMC Crypto 200

    1,443.40
    +4.51 (+0.31%)
     

Brain Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnostic Type, Cancer Type, and End User ; and Geography

·4-min read

The brain cancer diagnostics market was valued at US$ 844. 63 million in 2021 and is projected to reach US$ 2,476. 14 million by 2028; it is expected to grow at a CAGR of 16. 6 % from 2021 to 2028.

New York, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Brain Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnostic Type, Cancer Type, and End User ; and Geography" - https://www.reportlinker.com/p06176771/?utm_source=GNW

The growth of the brain cancer diagnostics market is attributed to factors such as an increase in the prevalence of brain cancer worldwide and technological advancements in brain cancer diagnostics. However, the market is likely to get impacted by the high cost involved in brain cancer diagnostics.

Brain cancer is caused due to extracellular growth of the cells in the brain that causes tumors.Tumors can be primary brain tumors and secondary brain tumors.

Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Symptoms of brain cancer include headaches, nausea, fatigue, drowsiness, and many more.
Cancer of the brain and nervous system is the tenth highest cause of mortality in men and women.According to the American Society of Clinical Oncology (ASCO), in 2021, around 24,530 adults (13,840 men and 10,690 women) are likely to be diagnosed with primary cancerous tumors of the brain and spinal cord in the US.

In a person’s lifetime, the chances of having this form of tumor are lesser than 1%.Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases.

Brain tumors can be fatal, have a severe impact on the quality of life, and ultimately turn a patient’s and their family’s lives.
Similarly, Cancer Research UK estimated that around 12,100 new cases of brain, other CNS, and intracranial tumors are diagnosed in the UK each year, which makes it around 33 cases per day (2015-2017).Brain tumors and other central nervous systems and intracranial tumors are the ninth most common malignancies in the UK, accounting for 3% of all new cancer cases (2017).

Also, it is the eighth most common cancer in females in the UK with around 6,100 new cases in 2017.In males in the UK, brain, other CNS, and intracranial tumors are the eleventh most common cancer, with about 5,800 new cases in 2017.

Incidence rates for brain tumors are projected to rise by 6% in the UK between 2014 and 2035, to 22 cases per 100,000 people by 2035.

The COVID-19 pandemic has become the most significant challenge across the world.It has disturbed various trades and businesses across the world.

As a result of the COVID-19 pandemic, many diagnostic departments have experienced a rapid decline in imaging case volumes.This has important implications on the short-term and long-term economic stability of neurological procedures across all healthcare practice settings.

Due to lockdowns imposed by governments across the world, many neurological procedures were delayed, and supply chain restrictions limited the availability of resources needed to deliver brain cancer diagnostic services.

Based on diagnostic type, the brain cancer diagnostics market is segmented into imaging test, lumbar puncture, biopsy, molecular testing, and others.The imaging test segment held the largest share of the market in 2021, and the molecular testing segment is anticipated to register the highest CAGR in the market during the forecast period.

The imaging test segment is further classified into magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET).
Based on cancer type, the brain cancer diagnostics market is segmented into Astrocytomas, Glioblastoma Multiforme, Ependymomas, and others.The Glioblastoma Multiforme segment held the largest share of the market in 2021, and the same segment is estimated to register the highest CAGR in the market during the forecast period.

Growth of the Glioblastoma Multiforme segment is attributed to the increased prevalence of this type of brain cancer.

Based on end user, the brain cancer diagnostics market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others.The hospitals segment held the largest share of the market in 2021.

The specialty clinics segment is estimated to register the highest CAGR in the market during the forecast period.
The American Society of Clinical Oncology, American Association of Neurological Surgeons, National Health Service, The Food and Drug Administration, The World Health Organization, Centers for Disease Control and Prevention, and Brain Tumor Registry of various countries are among the major primary and secondary sources referred to while preparing this report.
Read the full report: https://www.reportlinker.com/p06176771/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting